New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
07:43 EDTAEZSAeterna Zentaris signs co-promotion services agreement with ASCEND Therapeutics
Aeterna Zentaris announced a strategic co-promotion services agreement with ASCEND Therapeutics US. Under the terms of the agreement, expected to start in the Q4, Aeterna Zentaris will use its newly established commercial structure to market, in specific U.S. territories, ASCEND's EstroGel a non-patch transdermal, FDA approved and commercialized estrogen replacement therapy. For its part, ASCEND would market, in specific U.S. territories, MacrilenTM, Aeterna Zentaris' product for use in the evaluation of adult growth-hormone deficiency for which a New Drug Application is currently under review by the FDA, with a Prescription Drug User Fee Act date of November 5. In consideration for these co-promotion services, each party will be entitled to receive, from the other party, commissions on net sales of each other's product.
News For AEZS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
07:31 EDTAEZSAeterna Zentaris recruited 500 patients for pivotal Phase 3 ZoptEC study
Subscribe for More Information
June 25, 2015
07:37 EDTAEZSAeterna Zentaris selects Ergomed to conduct Phase 3 clinical trial of Macrilen
Aeterna Zentaris announced that it has executed a definitive agreement with Ergomed, pursuant to which Ergomed will manage the new, confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen, a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use